下载App
扫码立即下载
  • 下载App

    扫码立即下载

  • 在线客服

    登录后咨询在线客服
+
恭喜您!
成功领取价值超 5000港元/年的高级行情
前往体验 >>

Sonnet BioTherapeutics Appoints Ms. Lori McNeill to the Board of Directors and Formalizes the Company's Business Advisory Committee
十四行诗生物治疗公司任命洛里·麦克尼尔女士为董事会成员并正式成立公司的商业咨询委员会

Accesswire ·  {{timeTz}}
  • Ms. McNeill is a former executive of Pfizer and an entrepreneur with expertise in marketing and public relations; she will sit on the Board of Directors and serve as the Chairperson of Sonnet's newly formed Business Advisory Committee (BAC)
  • The BAC will advise the company on business collaborations, communications and interactions with the Federal Government
  • 麦克尼尔女士是辉瑞公司的前高管,也是一位在营销和公共关系方面有专长的企业家;她将成为董事会成员,并担任新成立的Sonnet商业咨询委员会(BAC)的主席
  • BAC将就与联邦政府的商业合作、沟通和互动向该公司提供建议

PRINCETON, NJ / ACCESSWIRE / September 26, 2022 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN), a clinical-stage company developing targeted immunotherapeutic drugs, announced today that Lori McNeill has been appointed to the Company's Board of Directors. Ms. McNeill's Board position will also round out the composition of the company's Business Advisory Committee (BAC), where she will serve as the Chairperson.

新泽西州普林斯顿/ACCESSWIRE/2022年9月26日/亚洲网加利福尼亚州圣何塞10月24日电开发定向免疫治疗药物的临床阶段公司十四行诗生物治疗控股公司(纳斯达克市场代码:SONN)今天宣布,洛里·麦克尼尔已被任命为公司董事会成员。麦克尼尔女士的董事会职位还将完善公司商业咨询委员会(BAC)的组成,她将在该委员会担任主席。

Lori McNeill has over 20 years' experience in the healthcare industry, 13 of which were at Pfizer that included working as the Chief of Staff of Global Operations in the Integrated Health Business unit. She additionally had responsibilities in senior marketing and managing operations. Ms. McNeill has held senior executive position at two startup companies and now as an entrepreneur heads a management consulting company. She has been recognized by several institutions: Ranked in Top 100 Global Women in Leadership - Global Council for the Promotion of International Trade, 2021; Changemakers Summit Award Winner, 2021; The State of Women in Leadership - Cover article for HR.com, 2020; and Pfizer International Innovation Excellence Award, 2011 and is currently Global Chairperson of Womenomics.

Lori McNeill在医疗保健行业拥有20多年的经验,其中13年曾在辉瑞工作,其中包括在综合健康业务部担任全球运营办公室主任。此外,她还负责高级营销和管理运营。麦克尼尔曾在两家初创公司担任高级管理职位,现在是一名企业家,经营着一家管理咨询公司。她曾获得多家机构的认可:2021年荣获全球100名女性领导力奖--全球国际贸易促进理事会;2021年荣获变革制造者峰会奖;2020年荣获HR.com《女性领导力状况》封面文章;2011年荣获辉瑞国际创新卓越奖,现任全球女性组学主席。

Sonnet's BAC will operate as an external body, guiding the company on strategic matters including external collaborations, communications and connecting with government programs, such as the Cancer Moonshot initiative. The BAC will consist of a senior pharma executive from Pfizer, a former congressman with over eight years' experience on Capitol Hill, a former White House aide, a successful entrepreneur and Sonnet's investor relations team. The role of the committee will be to assist in partnering efforts and to elevate the company's profile in the field of immune oncology through communication and leveraging the current and upcoming corporate milestones.

十四行诗的BAC将作为一个外部机构运作,在战略问题上指导公司,包括外部合作、沟通以及与政府项目的联系,如癌症登月计划。BAC将由辉瑞的一名高级制药高管、一名在国会山有八年以上经验的前国会议员、一名前白宫助手、一名成功的企业家和Sonnet的投资者关系团队组成。该委员会的作用将是协助合作努力,并通过沟通和利用当前和即将到来的公司里程碑来提升公司在免疫肿瘤学领域的形象。

"We believe the addition of Lori to the Board, combined with her oversight of the Business Advisory Committee, can further enhance and differentiate the company's operations, as we continue to elevate our standing in the field of immune oncology. This is particularly important in the context of having multiple clinical trials underway that we expect will be yielding data in the coming quarters," said Pankaj Mohan, Ph.D., Sonnet's Founder and Chief Executive Officer.

Sonnet的创始人兼首席执行官Pankaj Mohan博士说:“我们相信,Lori加入董事会,再加上她对商业咨询委员会的监督,可以进一步加强和区分公司的业务,因为我们将继续提升我们在免疫肿瘤学领域的地位。在我们预计将在未来几个季度产生数据的多项临床试验的背景下,这一点尤其重要。”

"This is certainly an exciting time at Sonnet and I am humbled by the opportunity to work with the company on its differentiated approach to innovating oncology therapeutics. As one of my primary responsibilities will be to chair the Business Advisory Committee, I will be leveraging my prior marketing experience to help raise awareness of the FHAB technology, with the intention of generating greater recognition for what I believe to be an exciting biotechnology platform." commented Ms. McNeill.

这当然是十四行诗的令人兴奋的时刻,我很荣幸有机会与该公司合作,以差异化的方式创新肿瘤疗法。由于我的主要职责之一将是担任商业咨询委员会主席,我将利用我以前的营销经验来帮助提高人们对FH我认为这是一个令人兴奋的生物技术平台。

About Sonnet BioTherapeutics Holdings, Inc.

关于Sonnet BioTreateutics控股公司

Sonnet BioTherapeutics is an oncology-focused biotechnology company with a proprietary platform for innovating biologic drugs of single or bispecific action. Known as FHAB (Fully Human Albumin Binding), the technology utilizes a fully human single chain antibody fragment (scFv) that binds to and "hitch-hikes" on human serum albumin (HSA) for transport to target tissues. Sonnet's FHAB was designed to specifically target tumor and lymphatic tissue, with an improved therapeutic window for optimizing the safety and efficacy of immune modulating biologic drugs. FHAB is the foundation of a modular, plug-and-play construct for potentiating a range of large molecule therapeutic classes, including cytokines, peptides, antibodies, and vaccines.

十四行诗生物治疗公司是一家专注于肿瘤学的生物技术公司,拥有创新单一或双特异性生物药物的专有平台。称为FHAB(完全人血清白蛋白结合),该技术利用与人血清白蛋白(HSA)结合并搭便车的全人单链抗体片段(ScFv)运输到目标组织。十四行诗FHAB是专门针对肿瘤和淋巴组织设计的,具有改进的治疗窗口,以优化免疫调节生物药物的安全性和有效性。FHAB是模块化、即插即用结构的基础,用于增强一系列大分子治疗类别,包括细胞因子、肽、抗体和疫苗。

Forward-Looking Statements

前瞻性陈述

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions.

本新闻稿包含1933年证券法第27A节和1934年证券交易法第21E节以及修订后的私人证券诉讼改革法所指的某些前瞻性陈述,包括与公司的产品开发、临床和监管时间表、市场机会、竞争地位、可能或假设的未来经营结果、商业战略、潜在增长机会以及其他预测性陈述有关的陈述。这些前瞻性陈述是基于对我们经营的行业和市场的当前预期、估计、预测和预测,以及管理层目前的信念和假设。

These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential, "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

这些表述可以通过使用前瞻性表述来识别,包括但不限于“预期”、“预期”、“打算”、“计划”、“相信”、“估计”、“潜在”、“预测”、“项目”、“应该”、“将”以及类似的表述和这些术语的否定。这些陈述与未来事件或我们的财务表现有关,涉及已知和未知的风险、不确定性和其他因素,这些风险、不确定性和其他因素可能导致实际结果、表现或成就与前瞻性陈述明示或暗示的任何未来结果、表现或成就大不相同。这些因素包括该公司向证券交易委员会提交的文件中所述的因素。告诫潜在投资者不要过度依赖此类前瞻性陈述,这些陈述仅在本新闻稿发布之日发表。公司不承担公开更新任何前瞻性陈述的义务,无论是由于新信息、未来事件还是其他原因。

Sonnet BioTherapeutics Investor Contact

十四行诗生物治疗公司投资者联系人

Michael V. Morabito, Ph.D.
Solebury Strategic Communications
917-936-8430
mmorabito@soleburystrat.com

迈克尔·V·莫拉比托博士
索尔伯里战略通信
917-936-8430
邮箱:mmorabito@soleburystrat.com

SOURCE: Sonnet BioTherapeutics, Inc.

资料来源:十四行诗生物治疗公司。


View source version on accesswire.com:
在accesswire.com上查看源代码版本:

本页的译文内容由软件翻译。富途将竭力但却不能保证翻译内容之准确和可靠,亦不会承担因任何不准确或遗漏而引起的任何损失或损害。

风险提示:以上内容仅作为作者或者嘉宾的观点,不代表富途的任何立场,不构成与富途相关的任何投资建议。在作出任何投资决定前,投资者应根据自身情况考虑投资产品相关的风险因素,并于需要时咨询专业投资顾问意见。富途竭力但不能证实上述内容的真实性、准确性和原创性,对此富途不做任何保证和承诺。